Peripheral blood CD8highCD57+ lymphocyte levels may predict outcome in melanoma patients treated with adjuvant interferon-α

Anticancer Research

Volumn 28, Issue 2 B, 2008, Pages 1139-1142

  Characiejus, Dainius ^a   Pašukoniene, Vita ^a   Auskaite, Renata Jonuš ^a   Azlauskaite, Nijolek ^a   Aleknavičius, Eduardas ^a   Mauricas, Mykolas ^a   Den Otter, Willem ^b  

^a VILNIUS UNIVERSITY   (Lithuania)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

CD8highCD57+ lymphocytes; Interferon ; Melanoma; Survival

Indexed keywords

ALPHA2B INTERFERON; REALDIRON; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; LYMPH NODE METASTASIS; MALE; MELANOMA; OUTCOME ASSESSMENT; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SURVIVAL TIME;

ADULT; AGED; ANTIGENS, CD57; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 42549133430     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Eggermont AM: Randomized trials in melanoma: an update. Surg Oncol Clin N Am 15: 439-451, 2006.
2. Stathopoulos GP, Baxevanis CN, Papadopoulos NG, Zarkadis IK, Papacostas P, Michailakis E, Tsiatas ML and Papamichail M: Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters. Anticancer Res 16: 3855-3860, 1996.
3. Characiejus D, Pasukoniene V, Kazlauskaite N, Valuckas KP, Petraitis T, Mauricas M and Den Otter W: Predictive value of CD8highCD57+ lymphocyte subset in interferon therapy of patients with renal cell carcinoma. Anticancer Res 22: 3679-3683, 2002.
4. Batliwalla FM, Bateman BA, Serrano D, Murray D, Macphail S, Maino VC, Ansel JC, Gregersen PK and Armstrong CA: A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med 4: 783-794, 1998.
5. Wang ECY, Moss PAH, Frodsham P, Lehner PJ, Bell JI and Borysiewicz LK: CD8highCD57+ lymphocytes in normal, healthy individuals are oligoclonal and respond to human cytomegalovirus. J Immunol 155: 5046-5056, 1995.
6. Matsuoka H, Yano K, Seo Y, Saito T, Tomoda H and Tsurumoto S: Usefulness of lymphocyte subset change as an indicator for predicting survival time and effectiveness of treatment with the immunopotentiator lentinan. Anticancer Res 15: 2291-2296, 1995.
7. Jorkov AS, Donskov F, Steiniche T, Ternesten-Bratel A, Naredi P, Hellstrand K and Hokland M: Immune response in blood and tumour tissue in patients with metastatic malignant melanoma treated with IL-2, IFN alpha and histamine dihydrochloride. Anticancer Res 23: 537-542, 2003.
8. Kolumam GA, Thomas S, Thompson LJ, Sprent J and Murali-Krishna K: Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202: 637-650, 2005.
9. Gogas H, Bafaloukos D, Ioannovich J, Skarlos D, Polyzos A, Fountzilas G, Kalofonos HP, Aravantinos G, Tsoutsos D, Panagiotou P, Frangia K, Petrakopoulou T and Pectasides D, Hellenic Cooperative Oncology Group: Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year - a Hellenic Cooperative Oncology Group study. Anticancer Res 24: 1947-1952, 2004.
10. Dondi E, Roue G, Yuste VJ, Susin SA and Pellegrini S: A dual role of IFN-alpha in the balance between proliferation and death of human CD4+ T lymphocytes during primary response. J Immunol 173: 3740-3747, 2004.
11. Le Priol Y, Puthier D, Lecureuil C, Combadiere C, Debre P, Nguyen C and Combadiere B: High cytotoxic and specific migratory potencies of senescent CD8+CD57+ cells in HIV-infected and uninfected individuals. J Immunol 177: 5145-5154, 2006.
12. Frassanito MA, Silvestris F, Cafforio P and Dammacco F: CD8+/CD57+ cells and apoptosis suppress T-cell functions in multiple myeloma. Br J Haematol 100: 469-477, 1998.
13. Raitakari M, Brown RD, Sze D, Yuen E, Barrow L, Nelson M, Pope B, Esdale W, Gibson J and Joshua DE: T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells. Br J Haematol 110: 203-209, 2000.
14. Ohkawa T, Seki S, Dobashi H, Koike Y, Habu Y, Ami K, Hiraide H and Sekine I: Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells. Immunology 103: 281-290, 2001.